"10" . . "Systemic antifungal therapy in children \u2013 trends, experience, recommendation"@en . "2"^^ . "Systemic antifungal therapy in children \u2013 trends, experience, recommendation"@en . . "Navzdory roz\u0161i\u0159uj\u00EDc\u00EDmu se spektru antimykotik nar\u016Fst\u00E1 mezi p\u0159\u00ED\u010Dinami morbidity a mortality u d\u011Bt\u00ED s v\u00FDznamnou prim\u00E1rn\u00ED \u010Di sekund\u00E1rn\u00ED poruchou imunity pod\u00EDl invazivn\u00EDch mykotick\u00FDch infekc\u00ED (IFI). Nej\u010Dast\u011Bj\u0161\u00EDmi p\u016Fvodci jsou Candida species nebo Aspergillus species, ale nar\u016Fst\u00E1 incidence rezistentn\u00EDch a m\u00E9n\u011B \u010Dast\u00FDch oportunn\u00EDch patogen\u016F. Limitem pou\u017Eit\u00ED \u0159ady nov\u00FDch \u00FA\u010Dinn\u00FDch antimykotik u d\u011Bt\u00ED (p\u0159edev\u0161\u00EDm novorozenc\u016F, kojenc\u016F a batolat) je nedostatek farmakokinetick\u00FDch a farmakodynamick\u00FDch dat. Proto n\u011Bkter\u00E1 antimykotika nemaj\u00ED licenci ani doporu\u010Den\u00E9 d\u00E1vkov\u00E1n\u00ED pro d\u011Bti, n\u011Bkter\u00E1 maj\u00ED doporu\u010Den\u00E1 d\u00E1vkov\u00E1n\u00ED pro d\u011Bti a\u017E od ur\u010Dit\u00E9ho v\u011Bku. V\u00FDsledkem \u0161patn\u011B zvolen\u00E9ho d\u00E1vkov\u00E1n\u00ED m\u016F\u017Ee b\u00FDt inefektivita p\u0159i podd\u00E1vkov\u00E1n\u00ED nebo ne\u00FAm\u011Brn\u00E9 toxick\u00E9 projevy p\u0159i p\u0159ed\u00E1vkov\u00E1n\u00ED anti mykotika. Komplexn\u00ED diagnostika a terapie IFI u d\u011Bt\u00ED je specifick\u00E1 a vy\u017Eaduje \u0161irok\u00FD t\u00FDm zku\u0161en\u00FDch specialist\u016F s pediatrickou erudic\u00ED."@cs . "invasive fungal infection; systemic therapy; antifungal agents; yeasts; molds; children"@en . . . . . "5" . "CZ - \u010Cesk\u00E1 republika" . "11130" . "6"^^ . . . . "Despite enlarged spectrum of antifungal drugs invasive fungal infection (IFI) as a proportion of morbidity and mortality in children with severe primary or secondary immunodeficiency is increasing. Candida species and Aspergillus species are the most common pathogens, but incidence of resistant and other less frequent opportunistic pathogens is increasing. Use of several new effective antifungal drugs in children (especially neonates, infants and toddlers) is limited by lack of pharmacokinetic and pharmacodynamic data. Therefore some of these drugs are not licensed in children and dosing is not established. Some recommendation is availab le only in children since certain age category. Inappropriate dosing may result in ineffective therapy when underdosed or excessive toxicity if overdosed. Complex diagnostics and therapy of IFI in children is specific and requires broad team of experienced specialists with proper pediatric background."@en . "345266" . . "Syst\u00E9mov\u00E1 antimykotick\u00E1 l\u00E9\u010Dba u d\u011Bt\u00ED \u2013 trendy, zku\u0161enosti, doporu\u010Den\u00ED"@cs . . "RIV/00216208:11130/09:5735!RIV10-MZ0-11130___" . "[D1D8B3DB1E96]" . "RIV/00216208:11130/09:5735" . "Sedl\u00E1\u010Dek, Petr" . . . . "Syst\u00E9mov\u00E1 antimykotick\u00E1 l\u00E9\u010Dba u d\u011Bt\u00ED \u2013 trendy, zku\u0161enosti, doporu\u010Den\u00ED" . "Syst\u00E9mov\u00E1 antimykotick\u00E1 l\u00E9\u010Dba u d\u011Bt\u00ED \u2013 trendy, zku\u0161enosti, doporu\u010Den\u00ED" . "Keslov\u00E1, Petra" . . . "Syst\u00E9mov\u00E1 antimykotick\u00E1 l\u00E9\u010Dba u d\u011Bt\u00ED \u2013 trendy, zku\u0161enosti, doporu\u010Den\u00ED"@cs . "1"^^ . . "Pediatrie pro praxi" . "Navzdory roz\u0161i\u0159uj\u00EDc\u00EDmu se spektru antimykotik nar\u016Fst\u00E1 mezi p\u0159\u00ED\u010Dinami morbidity a mortality u d\u011Bt\u00ED s v\u00FDznamnou prim\u00E1rn\u00ED \u010Di sekund\u00E1rn\u00ED poruchou imunity pod\u00EDl invazivn\u00EDch mykotick\u00FDch infekc\u00ED (IFI). Nej\u010Dast\u011Bj\u0161\u00EDmi p\u016Fvodci jsou Candida species nebo Aspergillus species, ale nar\u016Fst\u00E1 incidence rezistentn\u00EDch a m\u00E9n\u011B \u010Dast\u00FDch oportunn\u00EDch patogen\u016F. Limitem pou\u017Eit\u00ED \u0159ady nov\u00FDch \u00FA\u010Dinn\u00FDch antimykotik u d\u011Bt\u00ED (p\u0159edev\u0161\u00EDm novorozenc\u016F, kojenc\u016F a batolat) je nedostatek farmakokinetick\u00FDch a farmakodynamick\u00FDch dat. Proto n\u011Bkter\u00E1 antimykotika nemaj\u00ED licenci ani doporu\u010Den\u00E9 d\u00E1vkov\u00E1n\u00ED pro d\u011Bti, n\u011Bkter\u00E1 maj\u00ED doporu\u010Den\u00E1 d\u00E1vkov\u00E1n\u00ED pro d\u011Bti a\u017E od ur\u010Dit\u00E9ho v\u011Bku. V\u00FDsledkem \u0161patn\u011B zvolen\u00E9ho d\u00E1vkov\u00E1n\u00ED m\u016F\u017Ee b\u00FDt inefektivita p\u0159i podd\u00E1vkov\u00E1n\u00ED nebo ne\u00FAm\u011Brn\u00E9 toxick\u00E9 projevy p\u0159i p\u0159ed\u00E1vkov\u00E1n\u00ED anti mykotika. Komplexn\u00ED diagnostika a terapie IFI u d\u011Bt\u00ED je specifick\u00E1 a vy\u017Eaduje \u0161irok\u00FD t\u00FDm zku\u0161en\u00FDch specialist\u016F s pediatrickou erudic\u00ED." . "1213-0494" . . "Z(MZ0FNM2005)" .